Alnylam to Webcast Presentation at Upcoming Investor Conferences.CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at two investor conferences in September 2006: --NewsMakers in the Biotech Industry Conference on Thursday, September 7, 2006 at 11:30 a.m. ET at the Millennium Broadway Hotel, New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of ; and --Bear Stearns 19th Annual Healthcare Conference on Monday, September 11, 2006 at 8:00 a.m. ET at The Grand Hyatt, New York. A live audio webcast of these presentations will be available on the "Investors" section of the company's website, www.alnylam.com. A replay of the presentations will be posted on the Alnylam website approximately three hours after each event, and will be archived for 30 days. About Alnylam Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference RNA interference n. A process in which the introduction of double-stranded RNA into a cell inhibits the expression of genes. , or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus respiratory syncytial virus (sĭnsĭsh`əl): see cold, common. (RSV RSV respiratory syncytial virus; Rous sarcoma virus. RSV abbr. respiratory syncytial virus RSV 1 Respiratory syncytial virus, see there 2 Rous sarcoma virus, see there ) infection, which is the leading cause of hospitalization in infants in the U.S. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, and Novartis. The company, founded in 2002, maintains global headquarters in Cambridge, Massachusetts, and has an additional operating unit operating unit A type of operating company that engages in transactions with outsiders and that is owned by another business. For example, in 1995 the stockholders of Capital Cities/ABC approved a $19 billion merger with the Walt Disney Company, whereupon in Kulmbach, Germany. Alnylam is honored to be the "emerging/mid-cap" company recipient of the 2006 James D. Watson James Dewey Watson (born April 6, 1928) is an American molecular biologist, best known as one of the co-discoverers of the structure of DNA. Watson, Francis Crick, and Maurice Wilkins were awarded the 1962 Nobel Prize in Physiology or Medicine "for their discoveries concerning the Helix Award, the biotechnology industry's award for outstanding achievement. For more information, visit www.alnylam.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion